Flunisolide

Flunisolide
Clinical data
Trade names	Aerobid, Nasalide, Nasarel, others
Other names	6α-Fluoro-11β,16α,17,21-tetrahydroxypregna-1,4-diene-3,20-dione acetone cyclic 16,17-acetal
AHFS/Drugs.com	Monograph
MedlinePlus	a681048
Routes of; administration	Inhaled
ATC code	R01AD04 (WHO) R03BA03 (WHO);
Pharmacokinetic data
Protein binding	40% after inhalation
Elimination half-life	1.8 hours
Identifiers
	IUPAC name (1S,2S,4R,8S,9S,11S,12S,13R,19S)-19-fluoro-11-hydroxy-8-(2-hydroxyacetyl)-6,6,9,13-tetramethyl-5,7-dioxapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one;
CAS Number	3385-03-3 ;
PubChem CID	82153;
IUPHAR/BPS	7076;
DrugBank	DB00180 ;
ChemSpider	74144 ;
UNII	78M02AA8KF;
KEGG	D00324 ;
ChEBI	CHEBI:5106 ;
ChEMBL	ChEMBL1512 ;
CompTox Dashboard (EPA)	DTXSID1045534 ;
ECHA InfoCard	100.020.177
Chemical and physical data
Formula	C24H31FO6
Molar mass	434.504 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=C\1\C=C/[C@]2(/C(=C/1)[C@@H](F)C[C@H]3[C@H]4[C@](C[C@H](O)[C@H]23)([C@@]5(OC(O[C@@H]5C4)(C)C)C(=O)CO)C)C;
	InChI InChI=1S/C24H31FO6/c1-21(2)30-19-9-14-13-8-16(25)15-7-12(27)5-6-22(15,3)20(13)17(28)10-23(14,4)24(19,31-21)18(29)11-26/h5-7,13-14,16-17,19-20,26,28H,8-11H2,1-4H3/t13-,14-,16-,17-,19+,20+,22-,23-,24+/m0/s1 ; Key:XSFJVAJPIHIPKU-XWCQMRHXSA-N ;
	(what is this?) (verify)

Flunisolide (marketed as AeroBid among others) is a corticosteroid often prescribed as treatment for allergic rhinitis.^[1] Intranasal corticosteroids are the most effective medication for controlling symptoms.^[2]

The principal mechanism of action of flunisolide is to activate glucocorticoid receptors, meaning it has an anti-inflammatory action. The effects of topical corticosteroids is not immediate and requires regular use and at least a few days to start experiencing noticeable symptom relief. As-needed use has been shown to be not as effective as regular recommended use.^[2] Flunisolide should not be used in the presence of nasal infection. It should not be continued if there is no relief of symptoms after regular use over two to three weeks.^[3]

It was patented in 1958 and approved for medical use in 1978.^[4] It is on the World Health Organization's List of Essential Medicines.^[5]

^ "Flunisolide". DrugBank.
^ ^a ^b Wallace DV, Dykewicz MS, Bernstein DI, Blessing-Moore J, Cox L, Khan DA, et al. (August 2008). "The diagnosis and management of rhinitis: an updated practice parameter". The Journal of Allergy and Clinical Immunology. 122 (2 Suppl): S1-84. doi:10.1016/j.jaci.2008.06.003. PMID 18662584.
^ "Flunisolide Nasal Solution". DailyMed. U.S. National Library of Medicine.
^ Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 486. ISBN 9783527607495.
^ World Health Organization (2021). World Health Organization model list of essential medicines: 22nd list (2021). Geneva: World Health Organization. hdl:10665/345533. WHO/MHP/HPS/EML/2021.02.

[1] "Flunisolide". DrugBank.

[auto-2] Wallace DV, Dykewicz MS, Bernstein DI, Blessing-Moore J, Cox L, Khan DA, et al. (August 2008). "The diagnosis and management of rhinitis: an updated practice parameter". The Journal of Allergy and Clinical Immunology. 122 (2 Suppl): S1-84. doi:10.1016/j.jaci.2008.06.003. PMID 18662584.

[nih.gov-3] "Flunisolide Nasal Solution". DailyMed. U.S. National Library of Medicine.

[Fis2006-4] Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 486. ISBN 9783527607495.

[WHO22nd-5] World Health Organization (2021). World Health Organization model list of essential medicines: 22nd list (2021). Geneva: World Health Organization. hdl:10665/345533. WHO/MHP/HPS/EML/2021.02.

[1]

[2]

[3]

[4]

[5]

Flunisolide

From Wikipedia, the free encyclopedia · View on Wikipedia